ADMA Biologics Inc (NASDAQ:ADMA) Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 25.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 533,837 shares of the biotechnology company's stock after acquiring an additional 107,931 shares during the period. Calamos Advisors LLC owned 0.22% of ADMA Biologics worth $10,591,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ADMA. B Group Inc. acquired a new position in ADMA Biologics in the fourth quarter valued at about $39,231,000. Raymond James Financial Inc. acquired a new position in shares of ADMA Biologics in the 4th quarter worth approximately $19,076,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of ADMA Biologics by 57.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock worth $47,380,000 after acquiring an additional 1,013,456 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after acquiring an additional 643,661 shares during the last quarter. Finally, Man Group plc lifted its holdings in shares of ADMA Biologics by 305.5% in the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock worth $12,782,000 after acquiring an additional 561,507 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ADMA has been the topic of a number of research reports. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

Insider Activity

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the sale, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 464,621 shares of company stock worth $9,644,269. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Stock Down 2.2%

Shares of NASDAQ ADMA traded down $0.40 during midday trading on Monday, hitting $17.88. The company's stock had a trading volume of 1,830,295 shares, compared to its average volume of 3,701,131. The firm has a market capitalization of $4.27 billion, a price-to-earnings ratio of 21.04 and a beta of 0.43. ADMA Biologics Inc has a 1 year low of $10.21 and a 1 year high of $25.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The business's fifty day simple moving average is $20.11 and its two-hundred day simple moving average is $18.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. ADMA Biologics's quarterly revenue was up 40.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 earnings per share. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.